RxDoctor Payments Data

Jeffrey Perlmutter, MD

Nephrology · Rockville, MDNPI 1588651889

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (42.6%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Fresenius USA Marketing, Inc. at 46.1% of the total. Among nephrology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,996in general payments, 2019–2025

Across 36 payments — averaging $194.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$3K
  • AstraZeneca$3K
  • Vifor Pharma, Inc.$169
  • Amgen$76
  • Vertex$73
  • Sonavex, Inc.$64
  • plus $323 from 9 others

What the payments were for

  • Speaking & faculty fees$2,40034%
  • Grants$2,98143%
  • Travel & lodging$2824%
  • Food & beverage$1,27418%
  • Education$591%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,996 in reported general payments places this provider in the 90th percentile of 285 nephrology providers in Maryland.

See all nephrology providers in Maryland

Medicare billing

Part B allowed, 2024
$203,903
Medicare patients
382
Services billed
1,812

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol27$41,168
JardianceEmpagliflozin22$23,318
KerendiaFinerenone13$23,056
Sevelamer Carbonate42$14,183
Potassium Citrate ErPotassium Citrate18$3,863
Calcium Acetate38$3,429
Calcitriol71$1,390
Nifedipine ErNifedipine29$1,286
Losartan Potassium107$1,118
Amlodipine Besylate84$720
Metoprolol Succinate34$553
Gentamicin Sulfate14$547
Furosemide71$461
Atorvastatin Calcium13$259
Chlorthalidone15$244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$3,063$41,16827 claims
BayerKerendia$52$23,05613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 285 nephrology providers in Maryland.

Other nephrology in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →